MACK logo

MACK EBITDA

MACK Annual EBITDA

-$2.18 M
-$2000.00-0.09%

31 December 2023

MACK EBITDA Chart

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

MACK Quarterly EBITDA

-$669.00 K
-$179.00 K-36.53%

01 March 2024

MACK Quarterly EBITDA Chart

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

MACK TTM EBITDA

-$2.26 M
-$83.00 K-3.81%

01 March 2024

MACK TTM EBITDA Chart

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

MACK EBITDA Performance

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year-0.1%-26.0%+1.5%
3 y3 years+56.6%-26.0%+1.5%
5 y5 years+96.6%-26.0%+1.5%

MACK EBITDA High & Low

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-year
5 y5-year
alltimeall time+0.1%+41.4%+10.7%

Merrimack Pharmaceuticals EBITDA History

DateAnnualQuarterlyTTM
Mar 2024
-
-$669.00 K(+36.5%)
-$2.26 M(+3.8%)
Dec 2023
-$2.18 M(+0.1%)
-$490.00 K(-7.7%)
-$2.18 M(-5.1%)
Sept 2023
-
-$531.00 K(-6.7%)
-$2.29 M(+1.2%)
June 2023
-
-$569.00 K(-2.9%)
-$2.27 M(+3.8%)
Mar 2023
-
-$586.00 K(-3.5%)
-$2.18 M(+0.4%)
Dec 2022
-$2.17 M(-16.9%)
-$607.00 K(+20.4%)
-$2.17 M(+6.6%)
Sept 2022
-
-$504.00 K(+3.7%)
-$2.04 M(-5.3%)
June 2022
-
-$486.00 K(-15.8%)
-$2.15 M(-11.9%)
Mar 2022
-
-$577.00 K(+22.0%)
-$2.45 M(-6.5%)
Dec 2021
-$2.62 M(-47.8%)
-$473.00 K(-23.6%)
-$2.62 M(-13.6%)
Sept 2021
-
-$619.00 K(-20.4%)
-$3.03 M(-11.4%)
June 2021
-
-$778.00 K(+4.3%)
-$3.42 M(-10.6%)
Mar 2021
-
-$746.00 K(-15.8%)
-$3.82 M(-23.7%)
Dec 2020
-$5.01 M(-73.6%)
-$886.00 K(-12.0%)
-$5.01 M(-20.1%)
Sept 2020
-
-$1.01 M(-14.9%)
-$6.27 M(+5.1%)
June 2020
-
-$1.18 M(-38.8%)
-$5.97 M(-50.9%)
Mar 2020
-
-$1.94 M(-9.8%)
-$12.16 M(-36.0%)
Dec 2019
-$18.98 M(-70.1%)
-$2.15 M(+204.4%)
-$18.98 M(-39.3%)
Sept 2019
-
-$705.00 K(-90.4%)
-$31.26 M(-32.4%)
June 2019
-
-$7.37 M(-15.9%)
-$46.27 M(-16.9%)
Mar 2019
-
-$8.76 M(-39.3%)
-$55.65 M(-12.3%)
Dec 2018
-$63.43 M(-19.2%)
-$14.43 M(-8.2%)
-$63.43 M(-1.2%)
Sept 2018
-
-$15.71 M(-6.2%)
-$64.20 M(+19.9%)
June 2018
-
-$16.75 M(+1.3%)
-$53.53 M(-22.4%)
Mar 2018
-
-$16.54 M(+8.8%)
-$69.03 M(-12.1%)
Dec 2017
-$78.53 M(-44.8%)
-$15.20 M(+201.4%)
-$78.53 M(-24.8%)
Sept 2017
-
-$5.04 M(-84.4%)
-$104.42 M(-21.2%)
June 2017
-
-$32.25 M(+23.8%)
-$132.59 M(-1.8%)
Mar 2017
-
-$26.05 M(-36.6%)
-$134.98 M(-5.1%)
DateAnnualQuarterlyTTM
Dec 2016
-$142.16 M(+1.0%)
-$41.09 M(+23.7%)
-$142.16 M(-10.6%)
Sept 2016
-
-$33.21 M(-4.1%)
-$158.94 M(-1.5%)
June 2016
-
-$34.64 M(+4.3%)
-$161.42 M(+12.0%)
Mar 2016
-
-$33.23 M(-42.6%)
-$144.16 M(+3.2%)
Dec 2015
-$140.81 M(+126.7%)
-$57.87 M(+62.2%)
-$139.74 M(+61.8%)
Sept 2015
-
-$35.68 M(+105.3%)
-$86.38 M(+17.4%)
June 2015
-
-$17.38 M(-39.7%)
-$73.58 M(+7.3%)
Mar 2015
-
-$28.81 M(+540.1%)
-$68.56 M(+10.4%)
Dec 2014
-$62.11 M(-47.0%)
-$4.50 M(-80.3%)
-$62.11 M(-26.8%)
Sept 2014
-
-$22.88 M(+85.1%)
-$84.81 M(-12.7%)
June 2014
-
-$12.37 M(-44.7%)
-$97.14 M(-14.1%)
Mar 2014
-
-$22.36 M(-17.8%)
-$113.11 M(-3.5%)
Dec 2013
-$117.16 M(+33.8%)
-$27.21 M(-22.7%)
-$117.16 M(+3.2%)
Sept 2013
-
-$35.21 M(+24.2%)
-$113.57 M(+12.4%)
June 2013
-
-$28.34 M(+7.3%)
-$101.00 M(+10.1%)
Mar 2013
-
-$26.40 M(+11.8%)
-$91.74 M(+4.8%)
Dec 2012
-$87.54 M(+16.6%)
-$23.62 M(+4.3%)
-$87.54 M(+9.0%)
Sept 2012
-
-$22.64 M(+18.7%)
-$80.31 M(+7.2%)
June 2012
-
-$19.08 M(-14.1%)
-$74.95 M(-10.7%)
Mar 2012
-
-$22.20 M(+35.4%)
-$83.94 M(+13.5%)
Dec 2011
-$75.07 M(+75.4%)
-$16.39 M(-5.1%)
-$73.95 M(+10.4%)
Sept 2011
-
-$17.28 M(-38.4%)
-$67.00 M(+9.6%)
June 2011
-
-$28.07 M(+129.8%)
-$61.10 M(+38.4%)
Mar 2011
-
-$12.21 M(+29.5%)
-$44.13 M(+3.1%)
Dec 2010
-$42.80 M(-4.5%)
-$9.43 M(-17.1%)
-$42.80 M(+28.3%)
Sept 2010
-
-$11.38 M(+2.5%)
-$33.37 M(+51.8%)
June 2010
-
-$11.10 M(+2.0%)
-$21.99 M(+102.0%)
Mar 2010
-
-$10.88 M
-$10.88 M
Dec 2009
-$44.81 M
-
-

FAQ

  • What is Merrimack Pharmaceuticals annual earnings before interest, taxes, depreciation & amortization?
  • What is the all time high annual EBITDA for Merrimack Pharmaceuticals?
  • What is Merrimack Pharmaceuticals annual EBITDA year-on-year change?
  • What is Merrimack Pharmaceuticals quarterly earnings before interest, taxes, depreciation & amortization?
  • What is the all time high quarterly EBITDA for Merrimack Pharmaceuticals?
  • What is Merrimack Pharmaceuticals quarterly EBITDA year-on-year change?
  • What is Merrimack Pharmaceuticals TTM earnings before interest, taxes, depreciation & amortization?
  • What is the all time high TTM EBITDA for Merrimack Pharmaceuticals?
  • What is Merrimack Pharmaceuticals TTM EBITDA year-on-year change?

What is Merrimack Pharmaceuticals annual earnings before interest, taxes, depreciation & amortization?

The current annual EBITDA of MACK is -$2.18 M

What is the all time high annual EBITDA for Merrimack Pharmaceuticals?

Merrimack Pharmaceuticals all-time high annual earnings before interest, taxes, depreciation & amortization is -$2.17 M

What is Merrimack Pharmaceuticals annual EBITDA year-on-year change?

Over the past year, MACK annual earnings before interest, taxes, depreciation & amortization has changed by -$2000.00 (-0.09%)

What is Merrimack Pharmaceuticals quarterly earnings before interest, taxes, depreciation & amortization?

The current quarterly EBITDA of MACK is -$669.00 K

What is the all time high quarterly EBITDA for Merrimack Pharmaceuticals?

Merrimack Pharmaceuticals all-time high quarterly earnings before interest, taxes, depreciation & amortization is -$473.00 K

What is Merrimack Pharmaceuticals quarterly EBITDA year-on-year change?

Over the past year, MACK quarterly earnings before interest, taxes, depreciation & amortization has changed by -$138.00 K (-25.99%)

What is Merrimack Pharmaceuticals TTM earnings before interest, taxes, depreciation & amortization?

The current TTM EBITDA of MACK is -$2.26 M

What is the all time high TTM EBITDA for Merrimack Pharmaceuticals?

Merrimack Pharmaceuticals all-time high TTM earnings before interest, taxes, depreciation & amortization is -$2.04 M

What is Merrimack Pharmaceuticals TTM EBITDA year-on-year change?

Over the past year, MACK TTM earnings before interest, taxes, depreciation & amortization has changed by +$34.00 K (+1.48%)